Literature DB >> 21715031

Peak oxygen uptake correlates with disease severity and predicts outcome in adult patients with Ebstein's anomaly of the tricuspid valve.

Jelena Radojevic1, Ryo Inuzuka2, Rafael Alonso-Gonzalez3, Francesco Borgia3, Georgios Giannakoulas3, Matina Prapa2, Emmanouil Liodakis3, Wei Li3, Lorna Swan3, Gerhard Paul Diller2, Konstantinos Dimopoulos2, Michael A Gatzoulis2.   

Abstract

BACKGROUND: Ebstein's anomaly of the tricuspid valve often results in biventricular dysfunction and functional deterioration. Little is known about the relation between exercise capacity, disease severity and outcome in adults with Ebstein's anomaly.
METHODS: Data on all patients with Ebstein's anomaly of the tricuspid valve who underwent cardiopulmonary exercise testing in our tertiary center were collected. The relation between exercise parameters, anatomic severity (Glasgow outcome score) and the combined end-point of death, non-elective hospitalization and surgical repair was studied using Cox regression analysis.
RESULTS: A total of 51 adult patients fulfilled inclusion criteria (49% male, mean age 37.8±13.6 years). Mean peak oxygen uptake (peak VO2) was 63.2±18.7% of predicted, the slope of ventilation per unit of carbon dioxide output (VE/VCO2 slope) 37.4±11.4, heart rate reserve (HRR) 23.6±22.7 bpm. A significantly lower peak VO2 was found in patients with a higher Glasgow outcome score, higher cardiothoracic ratio and documented atrial shunt. Peak VO2 (HR for value <60% of predicted 3.47, 95% CI: 1.28–9.44, p=0.015) and HRR (HR for value <25 bpm 3.07, 95% CI: 1.24–7.61, p=0.016) were significant predictors of outcome, the former being the strongest on multivariable analysis.
CONCLUSIONS: Reduced exercise capacity in patients with Ebstein's anomaly relates to severity of the underlyingdisease and is a strong and independent predictor of outcome. Cardiopulmonary exercise testing should be incorporated in the follow-up and risk stratification of patients with this relatively uncommon and challenging cardiac defect.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21715031     DOI: 10.1016/j.ijcard.2011.06.047

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Ebstein anomaly: assessment, management, and timing of intervention.

Authors:  Puneeta Arya; Rebecca Beroukhim
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-10

2.  Non-invasive Hemodynamic CMR Parameters Predicting Maximal Exercise Capacity in 54 Patients with Ebstein's Anomaly.

Authors:  Christian Meierhofer; Andreas Kühn; Jan Müller; Nerejda Shehu; Alfred Hager; Stefan Martinoff; Heiko Stern; Peter Ewert; Manfred Vogt
Journal:  Pediatr Cardiol       Date:  2019-02-06       Impact factor: 1.655

3.  Association of Albuminuria With Major Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank.

Authors:  Saurabh Rajpal; Laith Alshawabkeh; Nureddin Almaddah; Caroline M Joyce; Keri Shafer; Michelle Gurvitz; Sushrut S Waikar; Finnian R Mc Causland; Michael J Landzberg; Alexander R Opotowsky
Journal:  JAMA Cardiol       Date:  2018-04-01       Impact factor: 14.676

Review 4.  Heart Failure Risk Predictions and Prognostic Factors in Adults With Congenital Heart Diseases.

Authors:  Patryk Leczycki; Maciej Banach; Marek Maciejewski; Agata Bielecka-Dabrowa
Journal:  Front Cardiovasc Med       Date:  2022-02-24

5.  Major adverse events and atrial tachycardia in Ebstein's anomaly predicted by cardiovascular magnetic resonance.

Authors:  Riikka Rydman; Yumi Shiina; Gerhard-Paul Diller; Koichiro Niwa; Wei Li; Hideki Uemura; Anselm Uebing; Umberto Barbero; Beatriz Bouzas; Sabine Ernst; Tom Wong; Dudley J Pennell; Michael A Gatzoulis; Sonya V Babu-Narayan
Journal:  Heart       Date:  2017-07-06       Impact factor: 5.994

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.